United Therapeutics CEO Martine A. Rothblatt disposes of shares worth $4,287,172.85

By Public Technologies
  • United Therapeutics Chairperson and CEO Martine A. Rothblatt reported option exercise and stock sales on Sept. 29, 2026.
  • Family trust acquired 9,500 shares at USD 117.76 via stock option exercise.
  • Trust sold 9,500 shares at prices from USD 472.0452 to USD 486.77.
  • Trust-held common stock position ended at 324,443 shares.
  • Trust-held stock options ended at 337,910 options, exercisable at USD 117.76.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. United Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001106578-26-000152), on September 30, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.